Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DQ1001 in Relapsed or Refractory Multiple Myeloma
NCT07622862Phase 1Not yet recruiting
- Sponsor
- Zhongshan Hospital (Xiamen), Fudan University
- Start
- Jun 2026
- Primary completion
- Sep 2027
01
Overview
Phase 1, open-label, single-arm trial of DQ1001 in multiple myeloma (MM), sponsored by Zhongshan Hospital (Xiamen), Fudan University. Primary endpoints: Dose-limiting Toxicity at 28 days, Adverse Events at 2 years and 1 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
DQ1001
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07622862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07622862.